Low prevalence of tissue detection of cefepime and daptomycin used as empirical treatment during revision for periprosthetic joint infections: results of a prospective multicenter study

Robineau, Olivier; Talagrand-Reboulh, E; Brunschweiler, B.; Jehl, F.; Beltrand, E.; Rousseau, Florence; Blondiaux, Nicolas; Grillon, Antoine; Joseph, C.; Lambotte, P; Boyer, Pierre; Senneville, Éric

doi:10.1007/s10096-021-04277-4

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To improve the rate of adequate EAT for OAI, we compared the number of OAI that would have been covered by a third-generation cephalosporin, cefepime, or imipenem instead of piperacillin-tazobactam ( Table 5 ). Not surprisingly, EAT using cefepime or imipenem as the beta-lactam provide a higher appropriateness than the one containing a third-generation cephalosporin (92%, 94.5%, and 78%, respectively), especially because of the narrow spectrum of third-generation cephalosporin compared to cefepime and imipenem ( 36 – 38 ).…”

Section: Discussionmentioning

confidence: 99%